Immunotherapy is defined as the prevention or treatment of disease with substances that stimulate the immune response. During last edition’s table talk, I learned about a new development in cancer research, CAR-T cells. In our immune system, we have two types of T-cells which are killer T-cells and helper T-cells. They work together to scan the cells and the environment in our bodies to destroy foreign invaders. However, when a cell becomes cancerous it is harder for T-cells to detect and destroy them because they behave like normal cells.
CAR-T cells are genetically altered T-cells. The T-cells are collected from the patient’s blood and given special receptors called chimeric antigen receptors (CAR). These receptors give the t-cell the ability to recognize antigens on tumor cells. After being created the CAR-T cells are infused into the patient. The T-cells multiply and guided by the receptors recognize and kill cancer cells. Patients have been known to go into remission after six months of this treatment.
Even though this is a breakthrough treatment in cancer research it comes with some risks. The CAR-T cells may end up malfunctioning which has caused death among two percent of the people that use this treatment.